FDA declines to approve Teva-MedinCell's risperidone injection for treating schizophrenia | Seeking Alpha
Teva and MedinCell Announce FDA Acceptance of New Drug Application for TV-46000/mdc-IRM as a Treatment for Patients with Schizophrenia | Business Wire
Teva and MedinCell Announce FDA Approval of UZEDY™ (risperidone) Extended-Release Injectable Suspension, a Long-Acting Subcutaneous Atypical Antipsychotic Injection, for the Treatment of Schizophrenia in Adults
Teva's long-acting schizophrenia drug rejected by FDA | pharmaphorum
Teva and MedinCell Announce FDA Approval of UZEDY™ (risperidone) Extended-Release Injectable Suspension, a Long-Acting Subcutaneous Atypical Antipsychotic Injection, for the Treatment of Schizophrenia in Adults
Uzedy risperidone 125Mg/0.35Ml
Teva Risperidone comprimé 4mg | Jean Coutu
La petite pharmacie de Nanterre - Médicament Risperidone Teva Sante 1 Mg/ml, Solution Buvable - NANTERRE
Teva and MedinCell Looking to Enter Increasingly Competitive LAI Schizophrenia Market - Clinical Trials Arena
Teva Moves Forward With LAI Olanzapine Trials :: Generics Bulletin
Teva Risperidone tablet 1mg | Jean Coutu
Medincell stock drops as FDA hits Teva with CRL on long-acting risperidone | BioWorld